Skip to main content
TipRanks
Go Ultimate75% OFF

Mette Kirstine Agger Insider Profile

4 Followers

Mette Kirstine Agger, Director at Lexeo Therapeutics, Inc., holds ― shares in Lexeo Therapeutics, Inc. (Ticker: LXEO), holds 1.43M shares in Enliven Therapeutics (Ticker: ELVN), holds 1.15M shares in Trevi Therapeutics (Ticker: TRVI).

Mette Kirstine Agger's Trading History

ELVN
Enliven Therapeutics
Mar 16, 2020Director, Ten Percent OwnerUninformative Buy―$68.23M
TRVI
Trevi Therapeutics
May 13, 2019DirectorUninformative Buy―$15.30M
SCPH
scPharmaceuticals
Nov 21, 2017―Uninformative Buy―$14.34M
LXEO
Lexeo Therapeutics, Inc.
―Director――

You May Also Like

Mette Kirstine Agger insider profile FAQ

What is the percentage of profitable transactions made by Mette Kirstine Agger?
The percentage of profitable transactions made by Mette Kirstine Agger is 0%.
What is the average return per transaction made by Mette Kirstine Agger?
The average return per transaction made by Mette Kirstine Agger is -48.50%.
What stocks does Mette Kirstine Agger hold?
Mette Kirstine Agger holds: LXEO, SCPH, TRVI, ELVN stocks.
What was Mette Kirstine Agger's most profitable transaction?
Mette Kirstine Agger’s most profitable transaction was an Informative Buy of ELVN stock on March 16, 2020. The return on the trade was -32.40%.
What is Mette Kirstine Agger's role in Lexeo Therapeutics, Inc.?
Mette Kirstine Agger's role in Lexeo Therapeutics, Inc. is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.